354 related articles for article (PubMed ID: 20825315)
1. Persistent malignant stem cells in del(5q) myelodysplasia in remission.
Tehranchi R; Woll PS; Anderson K; Buza-Vidas N; Mizukami T; Mead AJ; Astrand-Grundström I; Strömbeck B; Horvat A; Ferry H; Dhanda RS; Hast R; Rydén T; Vyas P; Göhring G; Schlegelberger B; Johansson B; Hellström-Lindberg E; List A; Nilsson L; Jacobsen SE
N Engl J Med; 2010 Sep; 363(11):1025-37. PubMed ID: 20825315
[TBL] [Abstract][Full Text] [Related]
2. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
[TBL] [Abstract][Full Text] [Related]
3. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
Mohr B; Oelschlaegel U; Thiede C; Stewart MM; Ehninger G; Platzbecker U
Haematologica; 2009 Mar; 94(3):430-1. PubMed ID: 19181778
[No Abstract] [Full Text] [Related]
4. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.
Venner CP; Woltosz JW; Nevill TJ; Deeg HJ; Caceres G; Platzbecker U; Scott BL; Sokol L; Sung S; List AF; Karsan A
Haematologica; 2013 Mar; 98(3):409-13. PubMed ID: 22929976
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
Göhring G; Giagounidis A; Büsche G; Hofmann W; Kreipe HH; Fenaux P; Hellström-Lindberg E; Schlegelberger B
Haematologica; 2011 Feb; 96(2):319-22. PubMed ID: 21109690
[TBL] [Abstract][Full Text] [Related]
8. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
9. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
[TBL] [Abstract][Full Text] [Related]
10. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
14. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Jädersten M; Karsan A
Haematologica; 2011 Feb; 96(2):177-80. PubMed ID: 21282717
[No Abstract] [Full Text] [Related]
15. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
16. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
Eclache V; Da Rocha A; Le Roux G; Fenaux P
Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
[TBL] [Abstract][Full Text] [Related]
17. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
19. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
[TBL] [Abstract][Full Text] [Related]
20. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
